[GENM] YoY Quarter Result on 31-Dec-2018 [#4]

Stock
[GENM] GENTING MALAYSIA BERHAD
Announcement Date
27-Feb-2019
Admission Sponsor
-
Sponsor
-
Financial Year
31-Dec-2018
Quarter
31-Dec-2018 [#4]
Profit Trend
QoQ- 148.21%
YoY- 60.25%
Quarter Report
Latest QR
Upcoming QR
GENM's Result
GENM's Financial Summary
View:
Show?
Quarter Result
31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 31/12/16 31/12/15 CAGR
Revenue 1,889,177 1,041,079 2,442,015 2,507,040 2,544,008 2,282,941 2,291,879 -3.16%
PBT 162,275 -285,089 286,861 400,411 477,321 1,796,767 357,846 -12.33%
Tax -38,195 26,902 -4,649 304,977 -47,001 -137,621 -11,840 21.53%
NP 124,080 -258,187 282,212 705,388 430,320 1,659,146 346,006 -15.69%
-
NP to SH 174,119 -240,848 299,743 720,139 449,387 1,686,334 338,558 -10.48%
-
Tax Rate 23.54% - 1.62% -76.17% 9.85% 7.66% 3.31% -
Total Cost 1,765,097 1,299,266 2,159,803 1,801,652 2,113,688 623,795 1,945,873 -1.61%
-
Net Worth 13,793,793 14,924,543 18,487,432 18,206,508 1,532,409 19,856,161 19,047,420 -5.23%
Dividend
31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 31/12/16 31/12/15 CAGR
Div 508,787 480,525 791,510 735,045 58,420 763,698 243,038 13.09%
Div Payout % 292.21% 0.00% 264.06% 102.07% 13.00% 45.29% 71.79% -
Equity
31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 31/12/16 31/12/15 CAGR
Net Worth 13,793,793 14,924,543 18,487,432 18,206,508 1,532,409 19,856,161 19,047,420 -5.23%
NOSH 5,938,040 5,938,040 5,938,040 5,938,040 5,938,040 5,938,040 5,652,053 0.82%
Ratio Analysis
31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 31/12/16 31/12/15 CAGR
NP Margin 6.57% -24.80% 11.56% 28.14% 16.92% 72.68% 15.10% -
ROE 1.26% -1.61% 1.62% 3.96% 29.33% 8.49% 1.78% -
Per Share
31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 31/12/16 31/12/15 CAGR
RPS 33.42 18.42 43.19 44.34 566.11 40.36 40.55 -3.16%
EPS 3.08 -4.26 5.30 12.74 7.94 29.81 5.99 -10.48%
DPS 9.00 8.50 14.00 13.00 13.00 13.50 4.30 13.08%
NAPS 2.44 2.64 3.27 3.22 3.41 3.51 3.37 -5.23%
Adjusted Per Share Value based on latest NOSH - 5,938,040
31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 31/12/16 31/12/15 CAGR
RPS 31.81 17.53 41.12 42.22 42.84 38.45 38.60 -3.17%
EPS 2.93 -4.06 5.05 12.13 7.57 28.40 5.70 -10.48%
DPS 8.57 8.09 13.33 12.38 0.98 12.86 4.09 13.10%
NAPS 2.323 2.5134 3.1134 3.0661 0.2581 3.3439 3.2077 -5.23%
Price Multiplier on Financial Quarter End Date
31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 31/12/16 31/12/15 CAGR
Date 31/12/21 31/12/20 31/12/19 31/12/18 29/12/17 30/12/16 31/12/15 -
Price 2.88 2.69 3.29 3.02 5.63 4.58 4.38 -
P/RPS 8.62 14.61 7.62 6.81 0.99 11.35 10.80 -3.68%
P/EPS 93.51 -63.14 62.05 23.71 5.63 15.36 73.12 4.18%
EY 1.07 -1.58 1.61 4.22 17.76 6.51 1.37 -4.03%
DY 3.13 3.16 4.26 4.30 2.31 2.95 0.98 21.33%
P/NAPS 1.18 1.02 1.01 0.94 1.65 1.30 1.30 -1.59%
Price Multiplier on Announcement Date
31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 31/12/16 31/12/15 CAGR
Date 24/02/22 25/02/21 27/02/20 27/02/19 27/02/18 23/02/17 23/02/16 -
Price 2.84 2.90 2.93 3.47 5.27 5.47 4.36 -
P/RPS 8.50 15.75 6.78 7.83 0.93 13.55 10.75 -3.83%
P/EPS 92.21 -68.07 55.26 27.24 5.27 18.35 72.79 4.01%
EY 1.08 -1.47 1.81 3.67 18.98 5.45 1.37 -3.88%
DY 3.17 2.93 4.78 3.75 2.47 2.47 0.99 21.38%
P/NAPS 1.16 1.10 0.90 1.08 1.55 1.56 1.29 -1.75%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ ⃤ & YoY ⃤ figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment